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Sinary rTisse from 323 ithaca-fixed and paraffin-embedded breast cancfs were assd for c-erbB-2
differtial polYMerase chain reation (dPCR). The sensitivity of dPCR was
using cel lines with c-erbB-2 ampfiation, and the relatonship betwn dPCR ratio value and gene copy
number was establshed. In clnical material the tehnue was not affected by the DNA contnbution of
normal tissue elments or by canmr DNA ploidy change. c-erbB-2 gne amwti was detected in 55% of
invasive cams and in 66% of ix situ cancse c-erbB-2 protein ovexession in breast cancer ceis, as
determined by sPecif immunohistochenistry, was only detected in 11% ofinvasive cancrs and 43% of in situ
cancem Comparisons show that a substantal number of cancrs with c-erbB2 ationlack detectable
protein overexesso. This illustrates the complx nature of c-erbB-2 gme di la in cancer and
sugests that multiple combinatons of biological events and consequences are possible.
Disregulation of the proto-oncogene c-erbB-2 (also known as
HER-2/neu) has been implicated in the aetiology of breast
cancer. Since the pubication of a study linking c-erbB-2 to
poor prognosis in breast cancer patients (Slamon et al., 1987)
there have been many studies examining c-erbB-2 gene
amplification, mRNA production and protein overexpression.
Recent reviews have collated the results from over 50 studies
and found a geneal agreement between them on the fre-
quency of c-erbB-2 disegulation in terms of gene
amplification and protein overexpresson, as measured by
Southern blotting and immunohistocmistry spectively
(Perren, 1991; Singleton & Strickler, 1992). However, there
are major differences in the association ofc-erbB-2 disregula-
tion with histopathological features and with prognosis, makc-
ing its involvement in cancer development and progression
difcult to determine. It is not clear whether differences in
results between studies have been the result of variations in
sample selection, experimental technique or genuine
biologically relevant disparity between populations.
Of the techniques for measuring gene amplification,
Southern or dot blotting suffers from the disadvantages that
microgram quantities of DNA are required for analysis and
tissue morphology is destroyed in the extration process.
Recent advances in polymerase chain reaction (PCR) tech-
nology have made possible the analysis of minute quantities
of DNA, with semiquantitative differential esimations
(dPCR) demonstrating increased gene copy number in cell
lines (Frye et al., 1989). The present work explores the
sensitivity of dPCR in detecting an increased gene copy
number in a large series of clnical cancers by extending the
application of this technique to paraffin-embedded tissues,
with a view to evaluating the relationship between c-erbB-2
gene amplification and expression.
Materak ad imtho
Study set
The study tissues (336 cases) were colleted from primary
operable (clinical stage I and II) breast cacers at routine
operations, which included mastectomy and excisional biopsy
for both palpable and non-palpable lesions. Sampks were
restricted to the age group 50-65 and were collecte over the
period of January 1988 to May 1990. They were fixed in
methacar (6:3:1 methanol-chloroform-acetic acid) over-
night at 4C, processed according to routine methods and
embedded in praffin- Control tissue (43 cases) was obtained
from breast tissue distant to the lesion site or from non-
cancer-bearing breasts. Pathological characterisation was
taken from overall evaluation of material used for routine
diagsis, and inchuded an evaluation of a 4pzm section
immediately adjacent to wctions taken for dPCR (see below).
This section confirmed the nature of the tissue used in the
PCR reaction, and in addition the cellularity of each speci-
men was assessed subjectively for the proportion of the
cancer cellular content and desgnated as either 1 = more
than 75%, 2 = 25-75% or 3=<25%. In some cases
samples of the lesion were taken and stored frozen in liquid
nitrogen for RNA analysis.
Flow cytometric analysis
Paraffin-embedded tumours were processed for DNA flow
cytometry according to the method of Hedley et al. (1983).
Briefly, two 50 pm sections were dewaxed using two changes
of xykne and rehydrated. The tissue was incubated for
30min at 3TC in 0.5% pepsin (Sigma) in 0.9% saline
adjusted to pH 1.5 with 2 N hydrochloric acid. The isolated
nuclei were counted and analysed usng an EPICS C flow
cytometer (Coulter Electronics, Hileah, FL, USA), after
staining with 0.1% propidium iodide containing 0.004%
RNAse. Ten thousand nucli were counted at 480 nm excita-
tion and the coefficient of variation calclated using STAT-
PACK software (Coulter Electonics).
Ploidy was as either diploid (DNA index, DI,
between 0.9 and 1.10) or aneuploid (DI > 1.10 and <1.90 or
>2.10). Tetraploids were classified as DI between 1.90 and
2.10 with more than 20% of the cells apparently in G2 plus
M phase of the cell cycle. For inclusion the coefficient of
variation for the peak value had to be less than 8%.
Cell lines and culture conditions
Human breast cancer cell lines known to have an
amplification of c-erbB-2 were used to calibrate the relation-
ship between differential PCR ratio values and gene copy
number. T'he epitheil cell line 21MT2 was obtained from R.
Sager (Dana-Farber Cancer Institute, Boston, MA, USA)
and contains a 40-fold increase of the c-erbB-2 gene (Band et
al., 1989). The cell line UISO BCA1 was obtained from R.R.
Mehta (University of Illinois, Chicago, IL, USA) and con-
tains a 10-fold increase in the c-erbB-2 gene (Sasi et al.,
1991).
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Each cell line was grown at 37C in air with 5% carbon
dioxide added. 21MT2 was cultured in alpha minimum essen-
ial medium (MEM) (Gibco) containing 10% fetal calf
serum, 2mM L-glutamie, I mM sodium pyruvate, 0.1 mM
non-essential amino acids, 1 igml-' ins 2.8 pM hyd-
rocortisone 12.5 ngml-' epidrmal growth factor and 10 mM
HEPES. UISO BCAI was cultured in Glasgow's minimum
essential medium (GMEM) (Gibco), 10% fetal calf serum
and 2 mM L-glutmine. For cahbration experiments, DNA
was prepared from each cdl line (Sambrook et al, 1989) and
was mixed with control DNA derived from normal placenta
(p258, one c-erb-B-2 gene copy), in proportions which gave a
series of known c-erbB-2 copy numbers. The 21MT2 DNA
was diluted to give c-erbB-2 copy numbers of 32, 24, 16, and
8, and UISO BCA1 was diuted to give copy numbers of9, 6,
5, 4 and 3.
Immunohistochemistry
Overexpression of c-erbB-2 was ascertained using the rabbit
polyclonal antibody, 21N, to the c-erbB-2 protein (Gullick et
al., 1987). Four micron sections of fixed tissue were dried at
56-C then stained in a thre-stag peroxidase-antiperoxidase
technique (Sternberger, 1986). The primary antibody, 21N,
was used at a concentration of 3.3igml'- in 0.1M Tris-
buffered sahne (pH 7.6) containing 5% normal swine serum.
Each section was incubated at room temperature for 90 min.
Endogenous peroxidase was blocked by exposure to 1%
hydrogen peroxide in nmthanol for 30min before staining.
Overexpression of c-erbB-2 was defined as the presence of
brown Staining of surface membrane of cancer cells. To score
positive, more than 10% of cells had to show moderate to
strong staining. Controls a known positive cas and
a negative control employing a preincubation of the antibody
with its corresponding peptide (1 mg ml-').
mRNA
Meger RNA was extracted from frozen tumour samples
and analysed by Northern blot (Thompson et al., 1990).
Twenty micrograms of total RNA was denatured with for-
mamide and formldhyde at 55-C for 20min and RNA
species separated by edetophoresis on a 1.1% agarose gel.
The RNA was tansferred to a nylon filter (hybond-N,
Amersham, UK) by capillary action usng 10 x SSC and
covaently fixed to the membrane using a UV tansil-
lIuminator. To detect c-erbB-2 mRNA the filters were hy-
bridised with 1107, a 1.7 kb fragment of v-erbB-2 (Semba et
al., 1985), according to the method of Church and Gilbert
(1984), washed to remove non-specifically attached probe and
exposed to preflashed Kodak XAR film at -70C. Filters
were stripped and reprobed with a-actin (Minty et al., 1981)
as an internal control for loading. The extent of hybridisa-
tion of radiolabelled probe to the mRNA specis was deter-
mined using densitometry and expressed with respect to hyb-
ridisation to the actin probe.
Primes and thepolymerase chain reaction
Primers used in the differential PCR are listed in Table I.
Tlhey were DNA sequences specific for interferon gamma
(IFN-y150), c-erbB-2 and interferon beta (IFN-P). The single-
copy reference sequence was the 150bp sequence from the
IFN-y gene. For dPCR four 10.pm sections offixed paraffin-
embedded tissue were added to 100id of lysis buffer (50 mM
Tris-HCL pH 8.4, 1 mM EDTA, 0.5% Tween 20) and boiled
for 8min (Hubbard & Anderson, 1993). Differential PCR
was performed on a Techne PHC3 thermal cycler incor-
porating 5 tl of prepred lysed paraffin section or 200 ng of
extracted DNA, 0.25 gtM each primer (except for primers for
IFN-P, 0.125gM), 200mM dNTPs (Pharmada), x 1 Taq
polymerase buffer (Northumbria Biotechnology Limited,
NBL), 1 unit of Taq polymerase (NBL) and 3 tCi of
[2PJCTP (New England Nuclear). Cycling parameters were
one cycle of 94-C for 5 mi 50C for 1 mi 70-C for 1 mi,
followed by 30 cycles of94C for 1 mi 50-C for 1 , 70-C
for 1 mi, and one cycle of 94-C for 1 min, 50C for 1 mi,
70 C for 5 min. Duplicate PCR products were separated by
size on 2% agarose gels, and stained with ethidium bromide.
Visible bands were excised, finely chopped and added to 5 ml
of Optiphase-safe scinillation fluid and radioactivity present
assessd as counts per minute (c.p.m.) on a Beckman scintil-
lation counter. A correction factor was applied to compen-
sate for the differences in numbers of CTP bases between
reference and test gene. Al specimens were assed in dupli-
cate experiments.
The results from dPCR are expressed as ratio values and
were callated by averaging the c.p.m. from duplicate gel
tracks and subtracting the average experimental blank. For
c-erbB-2 a correction factor of 1.25 was applied to compen-
sate for differences in dCTP content between IFN-y150 (69 C
bases) and c-erbB-2 (55 C bases). To ascertain the relative
quantity of c-erbB-2 gene with respect to the reference gene,
the corrected average c.p.m. for c-erbB-2 was divided by the
average c.p.m. for IFN-'yl5O, giving in each case a result
expressed as a ratio value. Similar correction factors were
calculated and applied to dPCR involving amplification of
IFN-P.
Reset
Validation ofd&fferential PCR method
Calibration ofratio values Differential PCR was assesed for
sensitivity and reproducibility in detemining gene copy
number. As defined here, 'one gene copy' corresponds to the
normal dipkoid content of one cell. The results of differential
PCR on the various DNA solutions of p258 and cell lines
21MT2 and UISO BCAI with known c-erbB-2 gene copy
number, using primers for IFN-150 and c-erbB-2, are shown
in Figure 1. A comparison of the known copy numbers in
each cell line sample and differential PCR ratio values
showed that increasing gene copy number resulted in increas-
ing ratio values, mean valus for I and 40 gene copy
numbers were 1.66 and 11.46 repcively. While comparison
of the ratio values obtained for given copy numbers shows
some variation between experiments, there was a consistent
irement in this value within each experint. Sampks with
large amplifiations (>32) showed increased variation
between duplicate tests. For the purposes of standardisation
it was consided best to work on a mean value for these
Table I DNA sequences of pnmers used in differential PCR
Gene Sequence Reference
c-erbB-2
Sense 5'-CCT CTG ACG TCC ATC ATC TC-3' Frye et al. (1989)
Antisense 5'-ATC TTC TGC TGC CGT CGC TT-3'
IFN--150
Sense 5'-TCTTTTCTT TCC CGA TAG GT-3' Frye et al. (1989)
Antisense 5'-CTG GGA TGC TCT TCG ACC TC-3'
IFN-4
Sense 5'-GTG TCT CCT CCA AAT TGC TC-3' Neubauer et al. (1992)
Antisense 5'-GCC ACA GGA GCTTCTGAC AC-3'436 A.L. HUBBARD et al.
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Cancer cellularity
c-erb B-2 copy number
Figure 1 Relationship between c-erbB-2 copy number
ential PCR ratio value. Each copy number was deriv
tion of DNA from c-erbB-2 amplified cell lines 21M1
BCAI with placental DNA (one copy). Each point
represents the mean of triplicate experiments.
experiments are represented by lines 1, 2 and 3.
experiments, depicted by open circles in Figure
mean ratio value of 2 approximated to five copie
2. Note that each ratio value is a derived value a
equate with but is directly proportional to
number.
Factors affecting dPCR ratio values Application
nique in a series of paraffin-embedded specime
stringent controls. Confirmation that IFN-y was ]
single-copy gene was obtained in 57 cancer and
specimens by performing differential PCR with
both IFN-yl50 and IFN-P. The ranges of r
detected were similar for cancers (0.81-1.9) and
sues (0.4-1.7), suggesting that IFN-y was presen
a single-copy gene.
Satisfactory analysis of DNA ploidy by floA
was obtained from 240 cancers. In 117 the phe
diploid, and 123 were aneuploid or tetraploid. Th
of amplification of c-erbB-2 in specimens assess
cytometry was found to be highest in cancers
diploid (60%), with lower percentages of aneu;
and tetraploid (42%) cancers being amplil
differences were not significant.
A third potentially confounding factor was th
effect of normal cells present within the cancer
haps reducing the detection frequency of amplifi
proportion of amplified and non-amplified cases
cancer ranked according to section cancer cellular
in Figure 2. Amplification was found in each of
including those specimens in which cancer cells
less than 25% of total cellularity.
c-erbB-2 amplification and overexpression in breast
Gene anplification determined by differential PCR
323 breast cancer specimens and 43 controls wer
c-erbB-2 amplification using primers for c-erbB-
y150. Figure 3 shows representative PCR produc
from fixed tissue specimens of three different canc
DNA extracted by routine phenol/choroform
from fresh tissue preserved at - 70°C from oi
cancers. Differential increase of c-erbB-2 product
amplification is illustrated, with corresponding rat
1.4, 2.1 and 3.6 for the fixed cancer tissue, 3.7 f
specimen 3 and 1.2 for control DNA.
Figure 2 Relationship between cancer cellularity and frequency
of c-erbB-2 amplification in 277 breast cancers. Cancer cellularity
was assessed visually as > 75% cancer cells = 1, 25-75% cancer
cells = 2, <25% = 3. 0, Specimens with a dPCR ratio value less
r and differ- than 2; *, Specimens considered to be amplified (dPCR ratio
red by dilu- value of 2 or above)
r2 or UISO
on line M
Individual track A 1 2 3 4 5
1. Thus a
s of c-erbB-
,nd does not
the copy
IFN-y 150bp
c-erb B-2 98bp of this tech-
ns required
present as a
27 control
primers for
ratio values
control tis-
t in both as
Fgue 3 Differential PCR products from IFN-y150 (150 bp) and
vcytometry c-erbB-2 (98 bp) size separated on a 2% agarose gel. Lanes are:
hnotype was A, BRL molecular weight marker V; 1. 2 and 3, three different
ie frequency cancers; 4, DNA from the same cancer as lane 3; 5. normal
sed by flow control DNA (p258). Differential PCR ratio values for lanes 1-5
which were are 1.3, 2.1, 3.5, 3.6 and 1.1 respectively. Lanes 2, 3 and 4 all
ploid (47%) show clear amplification of c-erbB-2 product.
fied. These
ie dilutional
tissue, per- The ratio values obtained using primers for c-erbB-2 and
ication. The IFN-yl50 from both normal and cancer tissues are shown in
,of invasive Figure 4. The ratio range for 43 normal tissues fell con-
ity is shown sistently between 0.6 and 1.9 (mean 1.2, s.d. 0.36), and
the groups, therefore values of 2 or above were considered to signify gene
constituted amplification. This value corresponds to approximately five
gene copies (see Figure 1), and indicates that dPCR, in its
present form, is unsuitable for exact specification of those
cancers
cases with low copy number (<5). The results of duplicate
experiments for each clinical case showed consistency for
A total of identification of gene amplification as being of low-medium
re tested for copy number (ratio value range 2-3) or high copy number
2 and IFN- (ratio greater than 3). In cancer tissues the range was
cts obtained 0.6-19.2 (n = 323), indicating copy numbers encompassed by
ers and one the range of copies assessed in the calibration (from I to 40).
procedures A total of 183 cancers had ratio values of 2 or above,
ne of these signifying gene amplification in at least 57% of this study set.
Ls indicating For 287 invasive cancers, the ratio values ranged from 0.6 to
tio values of 19.2 with ratio values ) 2 in 159 (55%), corresponding to
For DNA of low-medium copy number in 99 (34.5%) and high copy
number in 60 (20.5%). For 36 in situ cancers the ratio ranged
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from 1.0 to 8 with ratio values > 2 in 24 (66%), of which 15
(42%) were low-medium and nine (25%) were high copy
number.
Protein overexpression assessed by immunohistochemistry
Immunohistochemistry for c-erbB-2 overexpression was per-
formed on 336 breast cancer specimens. Overexpression of
c-erbB-2 was detected in 23 of 54 (43%) of in situ carcinomas
and in 31 of 282 (11%) invasive carcinomas. In cases in
which in situ and invasive forms of cancer were present on
the same slide, no detectable differences in the staining pat-
tern between them was observed. Staining was concentrated
on epithelial cell membranes and stained cells were present
evenly throughout the cancer, except in one cancer in which
focal staining of cancer cells was observed.
Overexpression was not observed in normal epithelial or
stromal cells.
Comparative evaluation of protein overexpression and gene
amplification A case comparison of gene amplification
determined by dPCR with protein expression determined by
immunohistochemistry is shown in Table II. Thirty-nine of
49 immunopositive cases (80%) had gene amplification (with
ratio values ranging from 2.0 to 19.2). There were ten cases
in which differential PCR did not detect gene amplification in
the presence of protein overexpression. However 146 of 274
immunonegative cases (53%) had PCR-detectable amplifi-
cation of the c-erbB-2 gene, and this included 43 cases with
ratio values >3, indicating high copy number. The range of
differential PCR values was similar between the immuno-
positive and immunonegative groups (Figure 5) and applied
to both in situ and invasive cancers. Of the 13 samples
assessed by immunohistochemistry but not available for
PCR, five were immunopositive.
mRNA measurement Specific messenger RNA was measured
in 26 breast cancer cases, and increased levels of c-erbB-2
mRNA corresponding to densitometry values four times con-
trol or greater were found in 11 cases (42%). The correlation
between c-erbB-2 mRNA levels and gene amplification and
overexpression is shown in Table III. All cases with positive
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immunohistochemistry contained elevated levels of c-erbB-2
mRNA. Furthermore, 4 of 19 cases negative for immuno-
histochemistry also had elevated levels of mRNA; gene
amplification determined by dPCR was present in two of
these cases.
Discussion
This study with fixed paraffin-embedded tissue has demon-
strated that dPCR is a highly sensitive technique for the
detection of gene amplification and is also sufficiently robust
to be applied to tumours of differing cellularity and DNA
ploidy. For invasive cancers the frequency of gene amplifi-
cation (55%) was considerably higher than anticipated from
reports of conventional methods based on Southern or dot
blotting techniques. In ten major studies of breast cancer,
each assessing 100 or more cancer cases, the frequency of
amplification varied between 17% and 23% (see review by
Singleton & Strickler, 1992). Because of the size of the dis-
parity some initial comment on comparability of methods is
appropriate.
Study of gene amplification is complicated by terminology
for an increased gene number, which may be expressed as
either a fold difference, increased copy number or both; fold
difference is equated with copy number in some reports (Ali
et al., 1988; Garcia et al., 1989). We have assumed that the
fold differences ascertained for the cell lines used in calibra-
tion of the dPCR are valid reflections of gene copy number,
and have therefore expressed the altered dPCR ratio values
as increased gene copy number. Owing to the arbitrary cut-
off point for 'amplification' outwith the range observed in
normals, dPCR would appear to lack the specificity to iden-
tify low copy number. Caution must be applied when ratio
values are extrapolated to gene copy number in clinical cases.
Experimental variation and approximations inherent to DNA
analysis, including Southern or dot blotting techniques, may
affect the precise relationship between classifications. Yet
studies using Southern or dot blotting claim to detect inc-
reases as low as 2-fold without quoting the full range of
values observed, the experimental variation in duplicate tests
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Figure 4 Distribution of differential PCR ratio values for c-
erbB-2 in 323 cancer tissues and 43 normal control tissues.
Figures in columns are expressed as percentage of cancers (-) or
percentage of normal controls (0).
Table 1I Comparison of c-erbB-2 protein overexpression measured
bv immunohistochemistrv and c-erbB-2 gene amplification measured
bv dPCR in 323 breast cancers
Overexpression No overexpression
Amplification 39 146
No amplification 10 128
The overall frequency of amplification is 57% and overexpression
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Fig_e 5 Distribution of dPCR ratio values for immunohisto-
chemistry positive (O) and negative cancers (0).
Table III Association of increased c-erbB-2 mRNA expression with
protein overexpression and gene amplification
Immunohistochemistry
Positive Negative
mRNA Positive Negative Positive Negative
Amplified 4 0 2 10
Non-amplified 3 0 2 5
All cancers with protein overexpression show elevated levels of
mRNA. Four of 19 cases which were negative for protein over-
expression have increased mRNA. Messenger RNA level appears to
be independent of gene amplification.
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or recorded cancer cellularity differences. It is of interest that
a large proportion of amplified cases show a low increase in
gene copy number by all techniques; for eaample, 44% have
2-5 copies on Southern blotting (Borg et al., 1990), while in
this study 61% have ratio values of2-3. There remains some
uncertainty about the most appropriate cut-off point on
which to base an amplified finding, but for the purposes of
this evaluation a ratio value of 2 was chosen, as this was
always above the values obtained for control samples. Rais-
ing the cut-off point to a ratio value of 2.5 would reduce the
numbers amplified to levels equivalent to those previously
reported. However, differences in amplifiation frequency
depending on technique have also been observed in studies of
the ovary. dPCR detected c-erbB-2 amplifiction in 40% of
cancers (Hruza et al., 1993); in contrast, pevious studies by
Southern blotting detected amplification in 1-26% of
ovarian cancers (Slamon et al., 1989; Zang et al., 1989;
Imyanitov et al., 1992). This suggsts that there may be
differences in sensitivity between these techniques. The pos-
sibility of artefactual elevation of dPCR ratio values in fixed
tissue extracts was examined by comparing them with sam-
ples of DNA from the corresponding fresh tissue in a subset
of cases, but we found no evidence for this (data not shown).
There is also the issue of selection bias towards larger size of
cancer where there is a requirment to submit tissue for
extraction in DNA analysis. This does not apply to dPCR
studies which, as in the present series, can be applid in a
consecutive manner.
A higher degree of sensitivity than in the present study was
claimed in a previous investigation of c-erbB-2 amplification
using dPCR (Frye et al., 1989). One extra copy (2-fold
increase) was detectable, but that study used high-quality,
homogeneous DNA derived from cell lnes in a single experi-
ment. Further developments of the technique on clinical
material classified amplfication in terms of fold differences,
the most sensitive level detecting a 2- to 4-fold increase in
c-erbB-2 product (Liu et al., 1992; Neubauer et al., 1992).
Those studies used a complex algorithm of experimetal
exclusions involing four different dPCR reactions resulting
in a selce population of cancers, and detected c-erbB-2
amplification in 48% of in situ canrs and in 21% of
invasive cancers (Liu et al., 1992). Details of interexperimen-
tal variation, ranges of dPCR ratio values and criteria for
exclusion at each step of the algorithm were not stated. This
makles direct comparison of amplation frequencies with
the current study difficult. In addition Liu et al. (1992)
restricted their series to stage H node-negative disease,
whereas the present series was a consecutive group of
operable cancer including both node-positive and node-
negative cases. However, despite the probklms of com-
parability, we consider that the technique as currently
applied has major potential to give a valid but different
perspetive of gene disregulation reklvant to study of the
development and progression of ancer.
Detection of overexpression of c-erbB-2 by immunohisto-
chemistry is subject to considerable variation between studies
(Singleton & Strickler, 1993) in part because of the different
primary antibodies, fixation methods, study set composition
and criteria for assessing positive staining. The dilution used
in this study of antibody 21N has been calibrated as detec-
ting around 12 or more copies of c-erbB-2 (Gusterson et al.,
1988), therefore cases with an amplification of between five
and 12 copies may appear to be immunonegative. Evidence
from the present mRNA studies supports this lmitation to
detecting expression as 21% of our immunonegative cases
tested had increased mRNA levels. That changes in methods
can affect the frequency of detection is evident from a recent
report by Poller et al. (1992), in which modification of
fixation and immunohistochemical techniques increased the
proportion of invasive cancers with c-erbB-2 overexpression
to 39.7% from 15% (Lovekin et al., 1991). As in other
studie, we found good correlation between overexpression
and amplification: 80% of immunopositive cancers had
detectable gene ampliication. However, the ranges of gene
copy values found by dPCR in immunopostive and immuno-
negative ancers of the current study set indicate that for
both invasive and in situ cancers amplfication does not
necessarily mean an equivalent overexpression, and some
cases with strong immunostaining showed normal or modest
icreases in gene copy numbers. This sugests that factors
which cause overexpression of c-erbB-2 in the absence of
gene amplication may also play a role when gene amplifi-
cation is present.
The disparity in frequency of c-erbB-2 gene activation
between in situ (around 44%) and invasive cancer (around
22%) noted in previous studies (see review by Singleton &
Stickler, 1992) is considerably diminished in the present
analysis, but the impliations for reklance in cancer progres-
sion are uncertain. An evaluation to test a hypothesis of
cancer natural history in the breast by Alred et al. (1992)
commented on c-erbB-2 overexpression in slce groups of
45 hyperplastic and dysplastic lesions as well as 708 in situ
and invasive cancers. They concluded that abnormal activa-
tion of the gene was likely to be a sigiint but not the sole
initiating factor for many cancers. The limitations of simple
immunohistochemistry as a measure of disregulated gene
activity have been recognised (Anderson, 1992; Wynford-
Thomas, 1992). Improved sensitivity of detecting abnormal
gene activity through fluorescent (or other methods of) in situ
hybridisation (Kallionemi et al., 1992; Smith et al., 1993) is
hlkely to reveal considerably more about the heterogeneity
and degree of gene disregulation within cell populations. The
potential to explore mcnisms of gene control by further
analysis of material slcted according to results of dPCR,
Northern analysis and/or immuohistochemistry is however
apparent from the results reported here.
The present tudies show that amplification ofc-erbB-2 is a
frequent event in breast cancer and that the relationship
between gene amplification and overexpression may be com-
plex. Although the insensitivity of current immunohisto-
chemistry in detecting small inreases in protein is a factor
compliating interpretation, it is neverteless likely that each
part of the repication/transcription/translation process can
be disregulated. Thus combininations of such events could
account for the distribution ofcases among the categories of
Table II1. Indeed, it appears that the fiequency of these
various disorders of gene number and expression is not
equivalent. A small percentage of cases overexpress c-erbB-2
in the absence ofamplfication, while a larger number fail to
show a detectable overexpression of the gene in the presence
of amplification even though a small number of this group
also have increased mRNA levels. Factors acting as pro-
moters or suppressors of gene function may directly affect
transcription regardless of the amplification status. Further
direct evidence of factors affecting transcription comes from
studies of breast cancer cell lines in which c-erbB-2 protein
can be down-regulated by oestrogen complexed with its
receptor (Russell and Hung, 1992). Inreased c-erbB-2
mRNA levels resulting from elevated amounts of a transcrip-
tion factor have also been observed in cancer cell ies which
have no detectable gene ampltion (Hollywood & Hurst,
1993). Other explanations of disorder include physical
damage to the gene, mutation or the absence of promoters.
This variety of biological events and consequences suggest
that a more realistic model to evaluate c-erbB-2 disregulation
in breast cancer must encompass a greater number of cir-
cumstances and consider the interaction of other biological
processes. The potential to study these in subgroups of
suitably characterised breast cancer cases is apparent.
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